Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 2, 2004, Pages 121-130

  De Maat, M M R ^a   De Boer, A ^b   Koks, C H W ^a   Mulder, J W ^a   Meenhorst, P L ^a   Van Gorp, E C M ^a   Mairuhu, A T A ^a   Huitema, A D R ^a   Beijnen, J H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Clinical pharmacist; Drug interactions; HIV outpatients; Intervention

Indexed keywords

AMPRENAVIR; ANTIARRHYTHMIC AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; EFAVIRENZ; INDINAVIR; LOPINAVIR; METHADONE; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; STAVUDINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DRUG BLOOD LEVEL; EVALUATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL INFORMATION; MEDICAL RECORD; MEDICAL SPECIALIST; OUTPATIENT; PHARMACEUTICAL CARE; PHARMACIST; PHYSICIAN; SIDE EFFECT;

ADULT; AMBULATORY CARE; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACEUTICAL SERVICES; VIRAL LOAD;

EID: 1842633681     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2003.00541.x     Document Type: Article

References (28)

1. Yeni PG, Hammer SM, Carpenter CCJ et al. (2002) Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA, 288, 222-235.
2. Bartlett JA, DeMasi R, Quinn J et al. (2001) Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS, 15, 1369-1377.
3. Lederberger B, Egger M, Opravil M et al. (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet, 353, 863-868.
4. Vittinghoff E, Scheer S, O'Malley P et al. (1999) Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. Journal of Infectious Diseases, 179, 717-720.
5. Berrey MM, Schacker T, Collier AC et al. (2001) Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. Journal of Infectious Diseases, 183, 1466-1475.
6. Smith PF, Dicenzo R, Morse GD (2001) Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clinical Pharmacokinetics, 40, 893-905.
7. Sommadossi J-P (1999) HIV protease inhibitors: pharmacologic and metabolic dinstinctions. AIDS, 13(Suppl. 1), S29-S40.
8. DePont Pharma. Sustiva™ (efavirenz) product information. Wilmington, DE. February 2000.
9. Roxane Laboratories, Inc. Viramune® (nevirapine) product information. Columbus, OH. November 2000.
10. Pharmacia & Upjohn Company. Rescriptor (delavirdine) product information. Kalamazoo, MI. July 1999.
11. Srinivas RV, Middlemas D, Flynn P et al. (1998) Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain efficacy in cell lines expressing these transporters. Antimicrobial Agents and Chemotherapy, 42, 3157-3162.
12. Huisman MT, Smit JW, Schinkel AH (2000) Significance of P-glycoprotein for the pharmacology and clinical use of protease inhibitors. AIDS, 14, 237-242.
13. Profit L, Eagling VA, Back DJ (1999) Modulation of P-glycoprotein functions in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS, 13, 1623-1627.
14. de Maat MMR, Frankfort SV, Mathôt RAA et al. (2002) Discrepancies between medical and pharmacy records for patients on anti-HIV drugs. Annals of Pharmacotherapy, 36, 410-415.
15. Gauthier I, Malone M, Lesar TS et al. (1997) Comparison of programs for preventing drug-nutrient interactions in hospitalized patients. American Journal of Health-System Pharmacy, 54, 405-411.
16. Hanlon JT, Weinburger M, Samsa GP et al. (1996) A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. American Journal of Medicine, 100, 428-437.
17. Hawkey CJ, Hodgson S, Norman A et al. (1990) Effect of reactive pharmacy intervention on quality of hospital prescribing. BMJ, 300, 986-990.
18. Monane M, Matthias DM, Nagle BA et al. (1998) Improving prescribing patterns for the elderly through an online drug utilization review intervention. A system linking the physician, pharmacist, and computer. JAMA, 280, 1249-1252.
19. Hatoum HT, Witte KW, Hutchinson RA (1992) Patient care contributions of clinical pharmacists in four ambulatory care clinics. Hospital Pharmacy, 27, 203-206.
20. Wang Chin JM, Muller RJ, Lucarelli CD (1995) A pharmacy intervention program: recognizing pharmacy's contribution to improving patient care. Hospital Pharmacy, 30, 120, 123-126, 129-130.
21. Garey KW, Teichner P (2000) Pharmacist intervention program for hospitalized patients with HIV infection. American Journal of Health-System Pharmacy, 57, 2283-2284.
22. Geletko SM, Poulakos MN (2002) Pharmaceutical services in an HIV clinic. American Journal of Health-System Pharmacy, 59, 709-713.
23. Herings RMC, Leufkens HGM (1998) Community pharmacy networks in pharmaco-epidemiology. In: Hartzema AG, Porta M, Tilson HH, eds. Pharmacoepidemiology: an introduction, 3rd edn. Cincinnati, OH: Harvey Whitney Books, 405-420.
24. De Maat MMR, Ekhart GC, Huitema ADR et al. (2003) Drug interactions between antiretroviral drugs and co-medicated agents. Clinical Pharmacokinetics, 42, 223-282.
25. Preston SL, Postelnick M, Purdy BD et al. (1998) Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. AIDS, 12, 228-230.
26. USPHS/IDSA (2001) Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. November 28, 2001. http://www.hivatis.org.
27. Kotler DP, Cockerell CJ, Britton CB et al. (1993) Organ-specific manifestations of HIV infection. AIDS, 7(Suppl. 1), S211-S224.
28. Lamson M, Macgregor T, Riska P et al. (1999) Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. Clinical Pharmacology and Therapeutics, 65, 137 (PI-79).